We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $1.06B
1-Year Est. Return 52.03%
This Fund
S&P 500
This Quarter Est. Return
+22.03%
1 Year Est. Return
+52.03%
3 Year Est. Return
+131.18%
5 Year Est. Return
+187.67%
10 Year Est. Return
+1,140.82%
AUM
$1.06B
AUM Growth
+$249M
Cap. Flow
+$137M
Cap. Flow %
12.89%
Top 10 Hldgs %
25.08%
Holding
106
New
20
Increased
41
Reduced
34
Closed
7

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$28.5M
2
MRK icon
Merck
MRK
+$25M
3
UNH icon
UnitedHealth
UNH
+$17.8M
4
JNJ icon
Johnson & Johnson
JNJ
+$16.9M
5
CNC icon
Centene
CNC
+$13M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$14.1M
2
LLY icon
Eli Lilly
LLY
+$11.6M
3
VEEV icon
Veeva Systems
VEEV
+$11.2M
4
ADPT icon
Adaptive Biotechnologies
ADPT
+$9.99M
5
BSX icon
Boston Scientific
BSX
+$9.48M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AXSM icon
26
Axsome Therapeutics
AXSM
$10.2B
$15.4M 1.46%
63,050
-750
-1% -$163K
DHR icon
27
Danaher
DHR
$158B
$15.3M 1.44%
80,252
+62,200
+345% +$11.3M
VRTX icon
28
Vertex Pharmaceuticals
VRTX
$133B
$15.2M 1.44%
30,685
-12,800
-29% -$5.67M
AVR
29
Anteris Technologies
AVR
$749M
$15.2M 1.43%
1,538,625
+100,000
+7% +$761K
NBIX icon
30
Neurocrine Biosciences
NBIX
$14.1B
$14.5M 1.37%
85,841
-15,000
-15% -$2.23M
PNTG icon
31
Pennant Group
PNTG
$1.42B
$13.7M 1.3%
371,471
+96,072
+35% +$3.14M
ISRG icon
32
Intuitive Surgical
ISRG
$143B
$13.7M 1.3%
34,500
-2,346
-6% -$1.02M
ELV icon
33
Elevance Health
ELV
$85.9B
$13.5M 1.27%
34,900
+2,600
+8% +$964K
LIVN icon
34
LivaNova
LIVN
$4.22B
$13.5M 1.27%
164,000
+9,000
+6% +$636K
COR icon
35
Cencora
COR
$58.6B
$13.2M 1.25%
46,778
-5,597
-11% -$1.61M
CRL icon
36
Charles River Laboratories
CRL
$14B
$13M 1.22%
57,200
+31,200
+120% +$5.56M
IDYA icon
37
IDEAYA Biosciences
IDYA
$3.54B
$12.8M 1.21%
343,800
+88,300
+35% +$2.7M
MCK icon
38
McKesson
MCK
$101B
$12.5M 1.18%
16,550
-300
-2% -$238K
SNDX icon
39
Syndax Pharmaceuticals
SNDX
$1.63B
$12.2M 1.16%
560,250
+181,000
+48% +$3.76M
BTSG icon
40
BrightSpring Health Services
BTSG
$11.2B
$11.6M 1.09%
165,896
+115,896
+232% +$6.44M
MDT icon
41
Medtronic
MDT
$113B
$11.3M 1.07%
145,000
+55,000
+61% +$4.44M
MLYS icon
42
Mineralys Therapeutics
MLYS
$2.29B
$11.2M 1.06%
416,371
+153,300
+58% +$4.21M
OSCR icon
43
Oscar Health
OSCR
$9.14B
$11.2M 1.06%
392,000
-268,000
-41% -$5.77M
RPRX icon
44
Royalty Pharma
RPRX
$25.9B
$11M 1.04%
197,000
-36,000
-15% -$1.87M
DXCM icon
45
DexCom
DXCM
$32.7B
$10.8M 1.02%
+160,000
New +$10.7M
ALGN icon
46
Align Technology
ALGN
$10.4B
$10.6M 1%
63,000
+55,500
+740% +$9.63M
SYRE icon
47
Spyre Therapeutics
SYRE
$7.56B
$10.6M 1%
+119,300
New +$8.71M
RLAY icon
48
Relay Therapeutics
RLAY
$3.83B
$10.6M 1%
566,000
+206,000
+57% +$2.99M
ARWR icon
49
Arrowhead Research
ARWR
$9.31B
$10.4M 0.98%
128,000
-16,500
-11% -$1.22M
A icon
50
Agilent Technologies
A
$48.7B
$9.96M 0.94%
75,000
+50,000
+200% +$6.09M
1
2
3 4 5

Similar funds

JSC
J. Stern & Co London, United Kingdom $1.06B AUM 11.76% 1-Year Est. Return
PCI
Planning Center Inc Moline, Illinois $1.06B AUM 12.82% 1-Year Est. Return
SAM
Synergy Asset Management Vancouver, Washington $1.06B AUM 36.26% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return
BDP
Brehaut David Pascal $1.06B AUM
GX
Greylock XIV Menlo Park, California $1.06B AUM
CIC
Cutler Investment Counsel Jacksonville, Oregon $1.06B AUM 20.29% 1-Year Est. Return
RCIM
Red Cedar Investment Management Grand Rapids, Michigan $1.06B AUM 30.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q2 2026 Portfolio in Review

As of Q2 2026, Rhenman & Partners Asset Management held 106 positions worth $1.06B, up 31% from $810M the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Rhenman & Partners Asset Management deployed $137M of net new capital in Q2 2026, opening 20 new positions and adding to 41 existing holdings. Its largest new stake was AstraZeneca: 151,500 shares worth $28.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $14.1M trimmed.

  • Rhenman & Partners Asset Management's largest Q2 2026 buy was AstraZeneca: 151,500 shares worth $28.5M.
  • Rhenman & Partners Asset Management added most to UnitedHealth in Q2 2026, an estimated $17.8M increase.
  • Rhenman & Partners Asset Management's biggest Q2 2026 reduction was Regeneron Pharmaceuticals, cutting an estimated $14.1M.
  • Rhenman & Partners Asset Management fully exited Adaptive Biotechnologies in Q2 2026, selling an estimated $9.99M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 25% of its $1.06B portfolio in Q2 2026.
  • Rhenman & Partners Asset Management opened 20 new positions and closed 7 in Q2 2026.
  • Rhenman & Partners Asset Management's portfolio value rose 31% quarter-over-quarter to $1.06B.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.